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Discovered 30 years ago, gamma delta (γδ) T-lymphocytes remain an intriguing and enig-
maticT-cell subset. Although in humans they comprise a small fraction of the total circulating
T-lymphocyte pool, they represent an important T-cell subset in tissues such as the liver,
with roles bridging the innate and adaptive immune systems. The associations of γδ
T-lymphocytes with chronic liver disease have been explored – however, there remain con-
flicting data as to whether theseT-cells are pathogenic or protective. In patients with some
forms of liver disease, their expansion in the periphery and especially in the liver may
indeed help pathogen clearance, while in other conditions their presence may, in contrast,
contribute to disease progression. γδ T-cells can also express CD161, a C-type lectin, and
such cells have been found to be involved in the pathogenesis of inflammatory disease.
CD161+ T-cells of diverse subsets are known to be enriched in the livers of patients with
chronic hepatitis C.This article serves to provide a review of the γδT-cell population and its
role in hepatitis C and other chronic liver diseases, and also explores a potential role of the
CD161 γδT-cells in liver diseases.+
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INTRODUCTION: γδ T-CELLS IN CONTEXT
The liver is the largest organ in the body and also one of the most
complex with multiple functional roles. Its dual vascular supply
includes the portal vein and the hepatic artery, and thus, it has a
prime location draining blood from the gut via the portal vein with
a constant exposure to antigens (Ag) and bacterial products from
the gut. However, it is not only harmful pathogens that challenge
the liver, it must recognize and tolerate harmless foreign (food-
derived) and self-Ags. Thus, the liver serves as a checkpoint to
promote tolerance to self and non-pathogenic stimuli and protect
against pathogens via the gut, and is therefore at risk of damage
from viruses and bacteria.
The liver can be affected by many acute insults such as drugs,
toxins, and acute viral infections; for example alcoholic hepati-
tis is one of the most florid manifestations of liver disease (1).
When the insult is a continuous or recurrent over a period of
time, a more chronic liver disease picture can develop leading
initially to fibrosis and eventually, if the stimulus persists, cirrho-
sis. The most common causes of chronic liver disease globally
include: hepatitis C virus (HCV), hepatitis B virus (HBV), alco-
holic liver disease, non-alcoholic fatty liver disease (NAFLD)/non-
alcoholic steatohepatitis (NASH), primary sclerosing cholangitis
(PSC), and primary biliary cirrhosis (PBC). Chronic liver disease
caused by any of these – with HCV a good example – can lead to a
broad spectrum of liver injury from mild fibrosis to severe fibro-
sis, compensated cirrhosis and finally decompensated cirrhosis
with major complications (e.g. esophageal variceal bleeding and
spontaneous bacterial peritonitis) and hepatocellular carcinoma
(HCC) development (2).
It is increasingly recognized that the liver has its own regional
immune system providing a local immune-surveillance network,
especially relevant to the gut. Blood from the gut drains via the
superior and inferior mesenteric veins into the portal vein and then
via the portal tracts and into the liver sinusoids and leaves via the
central vein. In the liver sinusoids, there is a complex network of
specialized immune-surveillance/antigen presenting cells (includ-
ing liver sinusoidal endothelial cells, Kupffer cells, and hepatic
stellate cells), which possess mechanisms allowing induction and
recruitment of innate and adaptive responses. Irrespective of the
causative agent of liver disease, once activated, the intrahepatic
immune system is typically thought to play a dual role both in
local host defense, and also in causing and/or propagating liver
disease.
The protective role of intrahepatic cellular immune responses
can be clearly seen in viral hepatitis. Spontaneous control of HCV
infection is linked to the activation of intrahepatic cellular immu-
nity and, conversely, the progression of HCV from an acute to
chronic infection (occurring in the majority of cases) relies on
evasion of cellular immunity (3). In acute HBV infection, a vigor-
ous response with robust generation of interferon (IFN-γ) and
tumor necrosis factor-alpha (TNF-α) can lead to clearance in
95% of cases in adults (4). Clearance of the virus in both these
contexts is typically accompanied by a flare in the hepatocyte-
derived amino transaminases, suggesting an aggressive immune
mediated response within the liver. Indeed, the degree of liver
damage correlates with the odds ratio of HCV clearance (5). The
relevant intrahepatic lymphocyte (IHL) populations have been
broadly characterized in humans, with the dominant intrahepatic
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population being the αβ T-cell populations. However, there also
exist many other subsets and gamma delta (γδ) T-cells comprise
15% of mouse and human IHLs (6).
Gamma delta T-cells represent approximately 2–10% of all
human T-cells in the peripheral blood (7) and are also found in
diverse tissues, most abundantly in gut epithelial tissue, and also
skin and bronchial epithelia. The position of γδT-cells at epithelial
barriers is strategic, i.e. continuously exposed to Ag and bacteria.
A specific subset of CD161+ γδ T-cell has been implicated in
inflammatory diseases such as multiple sclerosis (8, 9). CD161+
T-cells, however, have been found to be enriched in the livers of
patients with chronic HCV (10–15) and thus the specific features
of CD161+ γδ T-cells are of interest.
This article focuses on the γδ T-cell lymphocyte population
in HCV, drawing also on data from other related chronic liver
diseases.
γδ T-CELLS: THE BASIC TOOLKIT
Gamma delta T-cells were discovered after isolation of the TCR γ
chain gene (16) and represent the subgroup of T-cells that have γ-
and δ-glycoprotein chains linked by disulfide bonds rather than
the “conventional”αβ chain. Large numbers of different receptors
can be generated where different segments of genes: the variable
(V), diversity (D), and joining (J) segments combine at random to
produce numerous gene sequences – “VDJ recombination.” This
re-arrangement allows the generation of different receptors to a
variety of different Ags (17). γδ T-cells express CD3 – a complex
forming part of the TCR, but are normally CD4/CD8 negative
(double negative), although they may express variably CD4 or CD8
(18, 19). γδ T-cells, in contrast to αβ T-cells, do not require major
histocompatibility complex (MHC) presentation of Ag. Two main
subsets of γδ T-cells exist in humans determined by their Vδ chain
re-arrangement (although there are six subsets in total in humans).
Vδ1 cells are predominantly found in the gut and other periph-
eral tissues (such as lung, kidney, and spleen), whereas Vδ2 cells
represent the major fraction of circulating γδ cells in blood (20).
Vδ1 T-CELLS
Gamma delta-T-cells in the gut epithelium (predominantly the
Vδ1 subset) comprise up to 50% of the intra-epithelial lymphocyte
population (21), a population that is expanded in certain disease
states such as celiac disease (22). The Vδ1 T-cell population is
also expanded in intracellular bacterial infections (Mycobacterium
tuberculosis and Listeria monocytogenes), extracellular infections
(Borrelia burgdorferi) and have been shown to proliferate in
response to stimulation with Ags from cytomegalovirus (CMV)
(23, 24). Vδ1-expressing γδ T-cells have also found to be expanded
in the periphery in patients with acquired immunodeficiency syn-
drome (25). The Vδ1 subset recognize stress-inducible MHC class
1 chain-related Ags (MIC) A/B (26) or self-lipid presented Ags
by CD1c (27). These γδ T-cells can also be modulated by toll-
like receptor (TLR) ligands. TLR 1, 2, 3, 5, and 6 ligands can
act in combination with TCR stimulation to enhance chemokine
and cytokine production (28). The Vδ1 subset is not restricted to
the gut, but found at other sites including the skin (29). It has
recently been described that a subset of such cells can respond to
CD1d-lipid complexes in a manner analogous to iNKT cells (30).
Vδ2 T-CELLS
The Vδ2 subset (also known as Vδ2Vγ9) are unique to humans
and primates making up to 50–95% of the total γδ population
in the blood and further expanding in acute infections such as
M. tuberculosis, Salmonella, Listeria, Brucella, Malaria, and Toxo-
plasmosis even before other lymphocyte populations expand (31,
32). The Vδ2 subset can, however, also play an important role in
local disease processes in barriers such as the skin (33) acting as
a pro-inflammatory subset likely involved in the pathogenesis of
psoriatic lesions in the skin, for example, reduced circulating lev-
els of these cells are found in the periphery compared to healthy
controls or patients with atopic dermatitis.
The Vδ2 subset recognizes small non-peptide pyrophospho-
monoesters Ag, collectively known as “Phos-Ag” [the main one
being the microbial compound (e)-4-hydroxy-3-methyl-but-2-
enyl-pyrophosphate (HMB-PP) – an essential metabolite in path-
ogenic bacteria but not in the commensal human microbiota].
Bacteria synthesizing isopentenyl pyrophosphate (IPP) via the
classical mevalonate pathway such as Streptococcus and Staphylo-
coccus do not produce HMB-PP and thus do not recruit γδ T-cells,
whereas other bacteria such as L. monocytogenes and the parasite
Toxoplasma gondii, which synthesize IPP via the alternative non-
mevalonate pathway do indeed produce HMB-PP and thus recruit
γδ T-cells. The aminobisphosphonates (used in clinical practice
for bone strengthening in osteoporosis by the inhibition of bone
digestion by osteoclasts) are structurally related to IPP, and thus,
act as Vδ2 agonists (34). There have been only a few single non-
peptide ligands that have been shown to be both necessary and
sufficient to stimulate γδ T-cells, and indeed T-cell activation by
Phos-Ag often additionally requires cell-to-cell contact (7). Recent
data have indicated that butyrophilin 3A1 is a surface molecule
required for the presentation of Phos-Ag to γδ T-cells, although
the exact nature of the presenting pathway still needs to be fully
defined (35).
γδ-T-CELLS: FUNCTIONS IN VIVO
In addition to conventional type 1 T-cell functions, recently γδ
T-cells have been found to be a source of IL-17 (36) promoting
granulopoiesis and neutrophil recruitment to aid pathogen clear-
ance. The production of IL-17 by γδ cells in the gut epithelium can
lead to tight junction formation and mucin secretion in the face
of insults to the gut epithelium. They have also been found to pro-
duce IL-17 during TB infection in the lung (37). Along with IL-17,
γδ T-cells may also produce IL-22, granzyme B, perforin, TNF-α,
and IFN-γ (38–40). IL-17 producing γδ-T-cells may contribute to
the efficacy of anticancer chemotherapy (41); chemotherapy leads
to a rapid invasion of γδ-T-cells into the tumor bed, preceding
accumulation of Tc-1 cytotoxic T-lymphocytes. The anticancer
effect of the γδ-T-cells can be lost when there is a lack/deficiency
of IL-17A or IL-1R1.
Cytotoxicity of γδT-cells has been widely studied in the context
of tumors. Ex vivo expanded γδ T-cells from healthy volunteers
have been shown to be cytotoxic to high-grade glioblastomas
in vitro and in vivo (42). γδ T-cells have also been shown to medi-
ate killing of other tumor cells and represent an important effector
of the immune system with an anti-tumor peripheral surveillance
role (43). The Vδ2 T-cells are triggered by Phos-Ags (which are
Frontiers in Immunology | T Cell Biology August 2014 | Volume 5 | Article 400 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rajoriya et al. γδT-lymphocytes in chronic liver disease
indeed increased in malignancy) and produce cytokines typical
of Th-1, Th-2, or Th-17 cells (44–46), cross-talk with DCs (47)
and also have a direct cytotoxic effect via: perforin/granzyme,
Fas/FasL, TNF/TNF-R, and TRAIL-TRAIL-R pathways (29). The
killing capacity of the Vδ2 T-cells was improved by pre-treatment
of tumor target cells with aminobisphosphonates. The role of γδ
T-cells in the future of anticancer (including HCC) therapy may
be either via adoptive transfer (48) or in vivo stimulation and
recruitment through the aminobisphosphonates (49).
γδ T-CELLS AND HEPATITIS
Gamma delta T-cells localize preferentially in the liver compared
to blood (14) – thus, their contribution to liver disease remains
of great interest (see Table 1). Kenna and colleagues (13) showed
marked enrichment of γδ T-cells in normal liver specimens from
healthy donors compared to blood. In their study, they found a
clear enrichment of the Vδ3 subset (mean in liver 21%) compared
to blood, where it is very rarely found (0.5%). In healthy donors,
the dominant Vδ population was still found to be Vδ2, as in blood,
but relatively enriched compared to Vδ1 cells.
The presence of γδT-cells in chronic hepatitis biopsies has been
explored by Kasper and colleagues (51). In biopsies from 18 HBV
and 25 HCV patients, they found the predominant portal tract
infiltrate to be αβ T-cells; however, the lobular infiltration fre-
quencies between αβ and γδ T-cells were approximately equal.
Tseng and colleagues (52) studied T-cell lines generated from
HCV+ or HBV+ patient liver biopsies in vitro and found sig-
nificant numbers of γδ T-cells compared to expanded cells from
the non-virally infected liver. These γδ T-cells had high levels of
non-MHC-restricted cytotoxicity activity against primary hepa-
tocytes and also produced high levels of IL-8, IFN-γ, and TNF-α
when activated by anti-CD3. Similar findings were described by
Kanayama and colleagues (50), who found increased γδ T-cells in
immunohistochemical staining of liver tissue from patients with
chronic liver disease. Thus, although not the dominant T-cell infil-
trate in the liver, the γδ T-cell population has been found to be
enriched in the livers of patients with liver disease.
The intrahepatic γδ T-cell population was further described by
Agrati and colleagues (53), who studied 35 matched liver/blood
samples from patients with chronic HCV. There was a specific
compartmentalization of Vδ1 cells in preference to Vδ2 within
the liver with the cells expressing a memory/effector phenotype
(CD62L−CD45RO+CD95+). On mitogenic stimulation of these
cells they produced IFN-γ and IL-4. A higher frequency of IFN-γ
producing Vδ1 cells was associated with higher degree of necro-
inflammation, suggesting that these cells may indeed contribute
to intrahepatic pathogenesis and disease progression in HCV
patients. Similar observations were made in HCV/HIV co-infected
patients, correlating Vδ1 infiltration with hepatic inflammation
even in the setting of HAART (54).
The same group (53) further analyzed the antiviral functions
of the Vδ2 T-cells on Huh7 hepatoma cells carrying the subge-
nomic HCV replicon. Activation of the Vδ2 cells was associated
with a marked reduction of HCV RNA levels. The neutraliza-
tion of IFN-γ by antibodies revealed the importance of this
cytokine in inhibiting HCV replication. The inhibition of HCV
was increased by the use of aminobisphosphonates that activate
γδ T-cells – thus, pointing toward a potential future immunother-
apeutic strategy. These studies suggested that depending on the
type of Vδ chain expressed by the γδ T-cells, the cells might either
have a beneficial or deleterious effect in patients with chronic HCV
infection.
Par and colleagues (55) studied γδ T-cell responses in blood in
patients who had HCV disease compared to healthy controls, and
those patients who had cleared the virus with treatment. Patients
with chronic HCV showed a decreased percentage of Vδ2 cells, as
well as reduced perforin-positive T-lymphocytes compared to con-
trols or to those who had cleared HCV infection. These data again
suggested that impaired function and number of the Vδ2 γδT-cells
(although measured here in the periphery) may be involved in viral
persistence. The γδ T-cell populations have also been studied in
patients with chronic HBV (56). In patients with chronic HBV, the
percentage of Vδ2 T-cells negatively correlated with serum alanine
aminotransferase, aspartate transferase, and bilirubin suggesting
that reduction in the Vδ2 population in the periphery had a role
in the chronicity of HBV infection. Also, IFN-γ and TCR-γδ T-cell
cytotoxicity was lower in patients with chronic HBV compared to
healthy controls.
Relevant data also come from the liver transplant setting;
increased numbers of γδ T-cells have been identified in the circu-
lation of patients with stable liver graft function (57, 58, 60). Sim-
ilarly, other authors (59) identified an increase in the total circu-
lating peripheral γδ T-cell population in patients post-transplant
when compared to healthy controls. The main, stable, circulating
fraction of γδ T-cells was the Vδ1 T-cell population irrespective of
type of transplant (single liver or combined liver/kidney) or type
of immunosuppression. Interestingly, the physiological reversal of
the normal peripheral blood distribution (Vδ2>Vδ1) was par-
ticularly seen in patients with HCV and CMV positivity (rather
than Epstein–Barr virus or herpes simplex virus positive patients).
Thus, it was proposed that patients may have increased Vδ1 pop-
ulations in the transplant setting as a consequence of certain
chronic viral triggers. This Vδ1 cell population expressed CD4,
CD8, NKG2D, perforin, and IL-17A.
In another study, biological traits were compared between
patients who had immunosuppressive tolerance (i.e., who did
not develop rejection on immunosuppression withdrawal), those
who required ongoing immunosuppression and also healthy con-
trols (60). Genes encoding for γδ T-cells were found in those with
immune tolerance and these individuals were found to have signif-
icantly greater numbers of circulating (Vδ1) γδ T-cells than either
non-tolerant patients or healthy individuals. Thus, the γδ T-cells
may indeed play an important role in the post-liver transplant
setting, especially in patients who may manage to withdraw their
immunosuppression. The Vδ1 subset may expand in the setting
of post-transplantation due to chronic viral triggers in the face of
immunosuppression, or potentially the relative loss of Vδ2 cells
may reflect recruitment to the liver.
Gamma delta T-cells have also been studied in the context of
autoimmune liver disease (61). TheγδT-cell population frequency
was found to be comparable between the PBMCs of patients with
AIH (irrespective of disease state, i.e., active vs. remission) and
healthy control groups. However, interestingly they also observed
a reversal in the physiological Vδ2:Vδ1 ratio with more Vδ1 cells
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Table 1 | Summary of γδT-cell role and function in published studies in liver diseases.
Reference Area of
hepatology
Site of interest γδT-cell population findings
Kenna et al. (13) General Intrahepatic vs. peripheral γδ
T-cell population
Vδ3 T-cell population enriched compared to the periphery
Kanayama et al. (50) General Intrahepatic γδT-cell population Increased γδT-cells in immunohistochemical staining of patients with
chronic liver diseases
Kasper et al. (51) Viral (HBV/HCV) Intrahepatic γδT-cell population Equal frequencies of lobular infiltrates of αβ and γδT-cells in patients
Tseng et al. (52) Viral (HBV/HCV) γδT-cell generated from liver
biopsy in vitro
Significant numbers of γδT-cells in HCV/HBV infected patients compared
to expanded cells from the non-virally infected liver
Agrati et al. (53) Viral (HCV) γδT-cells from matched
liver/blood samples
Specific compartmentalization of Vδ1 cells in preference to Vδ2
γδ expressed a memory/effector phenotype (CD62L− CD45RO+ CD95+)
and produced IFN-γ and IL-4
Agrati et al. (82) Viral (HCV) Vδ2 T-cells on Huh7 hepatoma
cells carrying the subgenomic
HCV replicon
Activation of the Vδ2 cells was associated with a marked reduction of HCV
RNA levels
The inhibition of HCV was increased by the use of aminobisphosphonates
Pár et al. (55) Viral (HCV) Peripheral blood γδT-cell
population
Decreased percentage of Vδ2 cells, as well as reduced perforin-positive
T-lymphocytes compared to controls or to those who had cleared HCV
Chen et al. (56) Viral (HBV) Peripheral blood γδT-cell
population
Peripheral Vδ2 T-cells negatively correlated with liver function tests
IFN-γ and TCR-γδT-cell cytotoxicity were lower in patients with chronic
HBV compared to healthy controls
Malan-Borel et al. (57),
Koshiba et al. (58)
Transplant Peripheral blood γδT-cell
population
Increased numbers of γδT-cells have been identified in the circulation of
patients with stable liver graft function
Puig-Pey et al. (59) Transplant Peripheral blood γδT-cell
population
Increased total circulating γδT-cell population in patients post-transplant
vs. healthy controls (predominant Vδ1) T-cell population
Physiological reversal of blood Vδ2>Vδ1 was seen in patients with HCV
Increased Vδ1 populations in the post-transplant setting as a consequence
of certain chronic viral triggers
Vδ1 cell population expressed CD4, CD8, NKG2D, perforin, and IL-17A
Martinez-Llordella
et al. (60)
Transplant Peripheral blood γδT-cell
population
Increased Vδ1 peripheral circulating cells in patients in whom
immunosuppression could be withdrawn
Genes encoding for γδT-cells found in such patients when compared to
those in whom immunosuppression could not be withdrawn
Ferri et al. (61) Autoimmune
liver disease
Peripheral blood γδT-cell
population
Comparable frequencies between the PBMCs of patients with AIH
(irrespective of disease state-active vs. remission) and healthy control
groups
In AIH patients, reversal of the physiological Vδ2:Vδ1 ratio with more Vδ1
cells found in the periphery
The number of Vδ1 cells producing IFN-γ was significantly higher in
patients with AIH compared to healthy controls
Martins et al. (62) Autoimmune
liver disease
Peripheral blood γδT-cell
population
γδT-cells elevated numbers in the periphery in PBC/PSC when compared
to controls
Hoh et al. (63) Liver cancer Expanded ex vivo γδT-cell
population
γδT-cells expanded ex vivo (with aminobisphosphonate) and able to
recognize and lyse HCC (and hepatoblastoma) cell in a co-culture system
Bouet-Toussaint et al.
(64)
Liver cancer Expanded ex vivo γδT-cell
population
Vδ2 cells expanded ex vivo could lyse HCC cell cultures
Frontiers in Immunology | T Cell Biology August 2014 | Volume 5 | Article 400 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rajoriya et al. γδT-lymphocytes in chronic liver disease
FIGURE 1 | Summary of γδT-cell functions and the roles of specific subsets. The diagram indicates the origin of the γδT-cell pool, their phenotype, and the
distribution of the key subsets in tissues.
found in the periphery (p= 0.001), as in post-liver transplanta-
tion population previously described (59). In patients with AIH,
the γδ T-cell population expressed significantly more granzyme
B and the number of Vδ1 cells (but not Vδ2) producing IFN-γ
was significantly higher in patients with AIH compared to healthy
controls.
Since their function has been established in responses to certain
tumors,γδ T-cells have also been studied in targeting HCC – a fea-
ture of advanced liver disease associated with HCV (64). In a recent
study (63),γδ T-cells expanded ex vivo with an aminobisphospho-
nate were able to recognize and lyse HCC cell lines in co-culture
assays – thus, providing the rationale for targeted immunotherapy
in patients with HCC in the future.
Overall, these data suggest a clear disturbance of the nor-
mal distribution of γδ T-cells during chronic hepatitis C, with
an apparently consistent redistribution of γδ T-cells to the liver,
especially the lobular infiltrates. The impact of chronic hepati-
tis C appears to be differential according to the Vδ chain usage,
although this needs to be confirmed by further studies. Such
impacts are not restricted to HCV infection, and although a clear
potential as a pro-inflammatory subset in chronic inflammation
exists, in the absence of a relevant animal model where they can
be depleted, this is not currently proven. The summary of the role
and function of γδ T-cells in health and liver disease can be seen
in Figure 1, with the published studies in the chronic liver disease
setting summarised in Table 1.
CD161 AND γδ T-CELLS
CD161 [also known as killer lectin receptor subfamily B mem-
ber 1 (KLRB1)] is a C-type lectin membrane glycoprotein that is
expressed on the majority of NK cells, and approximately 24%
of peripheral T-cells (65). CD161 was originally identified as
the human homolog of the NKRP1A glycoproteins expressed on
rodent NK cells, demonstrating 46–47% homology with its rodent
counterparts. It is composed of a disulfide-linked homodimer of
40 kDa subunits, and has been shown to be expressed on both αβ
and γδ T-cells (66).
CD161 is present on CD4 and CD8 αβ T-cells with higher sur-
face density on CD8 T-cells (65). T-cells expressing CD161 can be
divided into further populations based on expression levels with
high and intermediate levels (also known as CD161 “bright” and
CD161 “mid” populations) (10, 67). CD161 T-cell expression has
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consistently been associated with a memory phenotype in adult
circulations not only in αβ T-cell populations (67–70) but also in
the γδ T-cell population (66). CD161 is expressed early in devel-
opment: a subset of T-cells in fetal liver express CD161 as does
a population of CD3+ thymocytes (65, 71). CD161+ CD4 T-
cells and CD8+ T-cells have been found in umbilical cord blood
(69, 71, 72).
CD161 expression is highly associated with liver-homing T cell
populations (11, 14). CD161 positivity has been found particularly
associated with mucosal-associated invariant T-cells (MAIT) (73)
that are abundant in humans (comprising up to 45% of liver lym-
phocytes). Staining with anti-Vα7.2 mAb and either CD161 or
IL-18R unequivocally identifies MAIT cells in the γδ− CD4−
CD3+ compartment. CD161 is also expressed on a significant
subset of HCV and HBV-specific T-cells (15), especially those in
the IHL compartment. CD161-expressing CD4+ T-cells are also
enriched in the liver (12). This cell population, like its CD8 coun-
terpart, is associated with RORγt expression and the potential for
IL-17 secretion (10, 69). Indeed, expression of CD161 marks all
human T-cells, whether CD4+ or CD8+, αβ, or γδ, capable of
producing IL-17 (66).
To date, there are no published studies of CD161+ γδ T-cells
in liver disease. However, some intriguing data are emerging from
other studies of tissue inflammation. CD161+γδ T-cells were first
studied by Battistini et al. (74), with CD94 the most common NK
receptor found on γδT-cells. However, some γδT-cells were found
also to express CD161 and hence, it was proposed that the CD161
phenotype could be acquired in vitro; this was confirmed in culture
experiments. On cross-linking CD161 on γδT-cells with antibody,
the γδ T-cells expressed large amounts of IFN-γ indicating the
molecule could deliver a stimulatory signal.
These data reveal that γδ T-cells are capable of regulation via
both the TCR and NK receptors, such as CD161, and hence act
in both adaptive and innate manners, respectively. In this way, γδ
T-cells have been described as part of the family of innate-like lym-
phocytes, which includes NKT and MAIT cells. Recently, MAIT
cells have been described to respond in an innate-like manner to
cytokine stimulation, independently of the TCR. The combina-
tion of IL-12 and IL-18 induced IFNγ from the CD161++ CD8+
T cell subset, including both MAIT and non-MAIT cells (75).
Innate-like γδ T-cells, which similarly respond selectively to IL-12
and IL-18, have also been identified by Wencker et al. (76). This
TCR-independent response may suggest a mechanism by which
γδ T-cells can be activated in diverse infection settings, even in the
absence of specific ligands. Indeed, response of γδ T-cells to var-
ious cytokines, and cytokine combinations, has previously been
reported (77, 78).
In addition to a costimulatory role, prior experiments have also
shown an involvement of CD161 in trans-endothelial migration
(79), with CD161+CD4 T-cells migrating further across endothe-
lial cell monolayers compared to CD161−ve CD4 T-cells, an effect
blocked by an anti-CD161 monoclonal antibody. CD161 expres-
sion was also found to be up-regulated on Vδ2 cells when cultured
with IL-12 [known to up-regulate CD161 (80)]. Transmigration
was then studied by culturing γδ T-cells with IL-2 or IL-12, and on
day 6 assessing transmigration through HUVEC monolayers using
a double transwell system. Vδ2 cell transmigration was higher and
faster and enhanced by culture with IL-12. When blocking the
FIGURE 2 | Summary of CD161+ γδT cell studies to date in health and disease. The diagram indicates the phenotype and function of CD161+ γδT cell
subsets, including the Vδ1 and Vδ2 subsets, and their potential role in disease where published data exist.
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cells with an anti-NKRP1A (191b8) monoclonal Ab, there was a
significant reduction in trans-endothelial migration. It was pos-
tulated that the CD161+ γδ T-cells did indeed localize to sites of
inflammation, and on exposure to IL-12 up-regulate expression
of CD161. In contrast, further experiments revealed that the Vδ1
subset used platelet endothelial cell adhesion molecule (PCAM1 or
CD31: an adhesion molecule involved in lymphocyte extravasion),
rather than CD161, for trans-endothelial migration (81).
These data indicate a specific functional role for CD161 on
γδ T-cells, notably the Vδ2 cell subset, and a specific set of func-
tions on CD161+ γδ T-cells in tissue inflammation. Since CD161
appears to be a general marker for liver-homing populations, the
specific role of CD161+ γδ T-cells in liver disease is therefore of
some interest for future studies. A summary of the role of CD161+
γδ T-cells can be seen in Figure 2.
CONCLUSION
It is clear that although a small non-dominant T-cell subset in the
human T-cell lineage, γδ T-cells play an important role in defense
against foreign pathogens. Their role as innate sentinels, guarding
against microbial invasion places them as a key T-cell subset in the
battle against pathogens not only in the gut at an epithelial level
but also, or potentially moreso, in the liver. Evidence is emerging
that depending on the type of liver disease, γδ T-cells may play a
role in disease pathogenesis. They have been shown to be effective
killers of cancer cells and thus patients with HCV-driven HCC
may be amenable to γδ T-cell-based immunotherapy.
Intriguingly, depending on their Vδ chain expression, the cells
may provide protection or induce tissue damage in the liver; in
particular, Vδ1 T-cells correlate with a higher necroinflammatory
score in patients with chronic HCV (53). Further delineation of
the relevant subsets may be of relevance in future. We postulate
this particularly applies to CD161 expression as this has been
linked to distinct functional attributes of the T cell, including
pro-inflammatory IL-17 production, and is also closely associ-
ated with liver-homing populations. Finally, further studies of
these and related intrahepatic T cell populations are relevant not
only to chronic HCV but also to other chronic liver disease set-
tings, especially those where therapeutic interventions are more
limited.
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